nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A2—Carmustine—lymphatic system cancer	0.101	0.289	CbGbCtD
Bortezomib—CYP2C19—Teniposide—lymphatic system cancer	0.0736	0.211	CbGbCtD
Bortezomib—CYP2C9—Teniposide—lymphatic system cancer	0.0612	0.175	CbGbCtD
Bortezomib—CYP3A4—Cytarabine—lymphatic system cancer	0.0361	0.103	CbGbCtD
Bortezomib—CYP3A4—Teniposide—lymphatic system cancer	0.0356	0.102	CbGbCtD
Bortezomib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0249	0.0712	CbGbCtD
Bortezomib—CYP3A4—Vincristine—lymphatic system cancer	0.0171	0.049	CbGbCtD
Bortezomib—PSMB8—Podofilox—Teniposide—lymphatic system cancer	0.00412	0.336	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Fludarabine—lymphatic system cancer	0.00292	0.238	CbGdCrCtD
Bortezomib—PSMB2—Azacitidine—Cytarabine—lymphatic system cancer	0.00276	0.225	CbGdCrCtD
Bortezomib—PSMB8—Vinorelbine—Vincristine—lymphatic system cancer	0.00245	0.2	CbGdCrCtD
Bortezomib—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000302	0.000473	CcSEcCtD
Bortezomib—Tremor—Carmustine—lymphatic system cancer	0.000301	0.000472	CcSEcCtD
Bortezomib—Oedema—Bleomycin—lymphatic system cancer	0.0003	0.000471	CcSEcCtD
Bortezomib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0003	0.000471	CcSEcCtD
Bortezomib—Erythema—Mitoxantrone—lymphatic system cancer	0.000299	0.000468	CcSEcCtD
Bortezomib—Infection—Bleomycin—lymphatic system cancer	0.000298	0.000468	CcSEcCtD
Bortezomib—Anaemia—Carmustine—lymphatic system cancer	0.000297	0.000465	CcSEcCtD
Bortezomib—Back pain—Vincristine—lymphatic system cancer	0.000297	0.000465	CcSEcCtD
Bortezomib—Vomiting—Teniposide—lymphatic system cancer	0.000296	0.000464	CcSEcCtD
Bortezomib—Sepsis—Methotrexate—lymphatic system cancer	0.000295	0.000463	CcSEcCtD
Bortezomib—Agitation—Carmustine—lymphatic system cancer	0.000295	0.000463	CcSEcCtD
Bortezomib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000294	0.000461	CcSEcCtD
Bortezomib—Asthenia—Fludarabine—lymphatic system cancer	0.000294	0.000461	CcSEcCtD
Bortezomib—Rash—Teniposide—lymphatic system cancer	0.000294	0.000461	CcSEcCtD
Bortezomib—Dermatitis—Teniposide—lymphatic system cancer	0.000294	0.00046	CcSEcCtD
Bortezomib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000292	0.000458	CcSEcCtD
Bortezomib—Headache—Teniposide—lymphatic system cancer	0.000292	0.000458	CcSEcCtD
Bortezomib—Pruritus—Fludarabine—lymphatic system cancer	0.00029	0.000454	CcSEcCtD
Bortezomib—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00029	0.000454	CcSEcCtD
Bortezomib—Back pain—Mitoxantrone—lymphatic system cancer	0.000289	0.000453	CcSEcCtD
Bortezomib—Leukopenia—Carmustine—lymphatic system cancer	0.000288	0.000451	CcSEcCtD
Bortezomib—Anorexia—Bleomycin—lymphatic system cancer	0.000286	0.000449	CcSEcCtD
Bortezomib—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000285	0.000447	CcSEcCtD
Bortezomib—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000284	0.000445	CcSEcCtD
Bortezomib—Anaemia—Vincristine—lymphatic system cancer	0.000283	0.000444	CcSEcCtD
Bortezomib—Agitation—Vincristine—lymphatic system cancer	0.000282	0.000442	CcSEcCtD
Bortezomib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000281	0.000441	CcSEcCtD
Bortezomib—Hypotension—Bleomycin—lymphatic system cancer	0.000281	0.00044	CcSEcCtD
Bortezomib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00028	0.000439	CcSEcCtD
Bortezomib—Convulsion—Carmustine—lymphatic system cancer	0.000278	0.000436	CcSEcCtD
Bortezomib—Hypertension—Carmustine—lymphatic system cancer	0.000277	0.000435	CcSEcCtD
Bortezomib—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000277	0.000434	CcSEcCtD
Bortezomib—Nausea—Teniposide—lymphatic system cancer	0.000277	0.000434	CcSEcCtD
Bortezomib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000276	0.000433	CcSEcCtD
Bortezomib—Vertigo—Vincristine—lymphatic system cancer	0.000276	0.000432	CcSEcCtD
Bortezomib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000275	0.000431	CcSEcCtD
Bortezomib—Leukopenia—Vincristine—lymphatic system cancer	0.000275	0.00043	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000274	0.000429	CcSEcCtD
Bortezomib—Chest pain—Carmustine—lymphatic system cancer	0.000274	0.000429	CcSEcCtD
Bortezomib—Myalgia—Carmustine—lymphatic system cancer	0.000274	0.000429	CcSEcCtD
Bortezomib—Anxiety—Carmustine—lymphatic system cancer	0.000273	0.000427	CcSEcCtD
Bortezomib—Paraesthesia—Bleomycin—lymphatic system cancer	0.00027	0.000423	CcSEcCtD
Bortezomib—Malaise—Mitoxantrone—lymphatic system cancer	0.000269	0.000422	CcSEcCtD
Bortezomib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000268	0.00042	CcSEcCtD
Bortezomib—Renal failure acute—Methotrexate—lymphatic system cancer	0.000268	0.000419	CcSEcCtD
Bortezomib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000267	0.000419	CcSEcCtD
Bortezomib—Convulsion—Vincristine—lymphatic system cancer	0.000266	0.000416	CcSEcCtD
Bortezomib—Hypertension—Vincristine—lymphatic system cancer	0.000265	0.000415	CcSEcCtD
Bortezomib—Confusional state—Carmustine—lymphatic system cancer	0.000264	0.000414	CcSEcCtD
Bortezomib—Oedema—Carmustine—lymphatic system cancer	0.000262	0.000411	CcSEcCtD
Bortezomib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000261	0.000409	CcSEcCtD
Bortezomib—Myalgia—Vincristine—lymphatic system cancer	0.000261	0.000409	CcSEcCtD
Bortezomib—Cough—Mitoxantrone—lymphatic system cancer	0.000261	0.000408	CcSEcCtD
Bortezomib—Infection—Carmustine—lymphatic system cancer	0.00026	0.000408	CcSEcCtD
Bortezomib—Vomiting—Fludarabine—lymphatic system cancer	0.00026	0.000408	CcSEcCtD
Bortezomib—Convulsion—Mitoxantrone—lymphatic system cancer	0.000259	0.000405	CcSEcCtD
Bortezomib—Rash—Fludarabine—lymphatic system cancer	0.000258	0.000405	CcSEcCtD
Bortezomib—Dermatitis—Fludarabine—lymphatic system cancer	0.000258	0.000404	CcSEcCtD
Bortezomib—Hypertension—Mitoxantrone—lymphatic system cancer	0.000258	0.000404	CcSEcCtD
Bortezomib—Pain—Bleomycin—lymphatic system cancer	0.000257	0.000402	CcSEcCtD
Bortezomib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000257	0.000402	CcSEcCtD
Bortezomib—Headache—Fludarabine—lymphatic system cancer	0.000257	0.000402	CcSEcCtD
Bortezomib—Tachycardia—Carmustine—lymphatic system cancer	0.000256	0.000401	CcSEcCtD
Bortezomib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000254	0.000398	CcSEcCtD
Bortezomib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000254	0.000398	CcSEcCtD
Bortezomib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000254	0.000398	CcSEcCtD
Bortezomib—Anxiety—Mitoxantrone—lymphatic system cancer	0.000253	0.000397	CcSEcCtD
Bortezomib—Lethargy—Methotrexate—lymphatic system cancer	0.000252	0.000395	CcSEcCtD
Bortezomib—Discomfort—Mitoxantrone—lymphatic system cancer	0.000251	0.000394	CcSEcCtD
Bortezomib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00025	0.000392	CcSEcCtD
Bortezomib—Oedema—Vincristine—lymphatic system cancer	0.00025	0.000392	CcSEcCtD
Bortezomib—Anorexia—Carmustine—lymphatic system cancer	0.00025	0.000392	CcSEcCtD
Bortezomib—Infection—Vincristine—lymphatic system cancer	0.000249	0.00039	CcSEcCtD
Bortezomib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000248	0.000388	CcSEcCtD
Bortezomib—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000247	0.000387	CcSEcCtD
Bortezomib—Confusional state—Mitoxantrone—lymphatic system cancer	0.000246	0.000385	CcSEcCtD
Bortezomib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000245	0.000385	CcSEcCtD
Bortezomib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000245	0.000384	CcSEcCtD
Bortezomib—Hypotension—Carmustine—lymphatic system cancer	0.000245	0.000384	CcSEcCtD
Bortezomib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000244	0.000382	CcSEcCtD
Bortezomib—Oedema—Mitoxantrone—lymphatic system cancer	0.000244	0.000382	CcSEcCtD
Bortezomib—Nausea—Fludarabine—lymphatic system cancer	0.000243	0.000381	CcSEcCtD
Bortezomib—Infection—Mitoxantrone—lymphatic system cancer	0.000242	0.000379	CcSEcCtD
Bortezomib—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000242	0.000379	CcSEcCtD
Bortezomib—Shock—Mitoxantrone—lymphatic system cancer	0.00024	0.000376	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000239	0.000374	CcSEcCtD
Bortezomib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000239	0.000374	CcSEcCtD
Bortezomib—Urticaria—Bleomycin—lymphatic system cancer	0.000239	0.000374	CcSEcCtD
Bortezomib—Anorexia—Vincristine—lymphatic system cancer	0.000239	0.000374	CcSEcCtD
Bortezomib—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000238	0.000373	CcSEcCtD
Bortezomib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000237	0.000372	CcSEcCtD
Bortezomib—Insomnia—Carmustine—lymphatic system cancer	0.000237	0.000372	CcSEcCtD
Bortezomib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000237	0.000371	CcSEcCtD
Bortezomib—Irritability—Methotrexate—lymphatic system cancer	0.000236	0.00037	CcSEcCtD
Bortezomib—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000236	0.000369	CcSEcCtD
Bortezomib—Paraesthesia—Carmustine—lymphatic system cancer	0.000235	0.000369	CcSEcCtD
Bortezomib—Hypotension—Vincristine—lymphatic system cancer	0.000234	0.000366	CcSEcCtD
Bortezomib—Dyspnoea—Carmustine—lymphatic system cancer	0.000234	0.000366	CcSEcCtD
Bortezomib—Anorexia—Mitoxantrone—lymphatic system cancer	0.000232	0.000364	CcSEcCtD
Bortezomib—Ataxia—Methotrexate—lymphatic system cancer	0.000232	0.000364	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000228	0.000357	CcSEcCtD
Bortezomib—Decreased appetite—Carmustine—lymphatic system cancer	0.000228	0.000357	CcSEcCtD
Bortezomib—Hypotension—Mitoxantrone—lymphatic system cancer	0.000228	0.000357	CcSEcCtD
Bortezomib—Insomnia—Vincristine—lymphatic system cancer	0.000226	0.000355	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000226	0.000355	CcSEcCtD
Bortezomib—Paraesthesia—Vincristine—lymphatic system cancer	0.000225	0.000352	CcSEcCtD
Bortezomib—Pain—Carmustine—lymphatic system cancer	0.000224	0.000351	CcSEcCtD
Bortezomib—Constipation—Carmustine—lymphatic system cancer	0.000224	0.000351	CcSEcCtD
Bortezomib—Breast disorder—Methotrexate—lymphatic system cancer	0.000223	0.00035	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000223	0.000349	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000222	0.000348	CcSEcCtD
Bortezomib—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000221	0.000347	CcSEcCtD
Bortezomib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000219	0.000343	CcSEcCtD
Bortezomib—Decreased appetite—Vincristine—lymphatic system cancer	0.000218	0.000341	CcSEcCtD
Bortezomib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000217	0.000341	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000216	0.000339	CcSEcCtD
Bortezomib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000216	0.000339	CcSEcCtD
Bortezomib—Fatigue—Vincristine—lymphatic system cancer	0.000216	0.000338	CcSEcCtD
Bortezomib—Asthenia—Bleomycin—lymphatic system cancer	0.000216	0.000338	CcSEcCtD
Bortezomib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000215	0.000336	CcSEcCtD
Bortezomib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000214	0.000336	CcSEcCtD
Bortezomib—Constipation—Vincristine—lymphatic system cancer	0.000214	0.000335	CcSEcCtD
Bortezomib—Pain—Vincristine—lymphatic system cancer	0.000214	0.000335	CcSEcCtD
Bortezomib—Pruritus—Bleomycin—lymphatic system cancer	0.000213	0.000333	CcSEcCtD
Bortezomib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000212	0.000332	CcSEcCtD
Bortezomib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00021	0.000329	CcSEcCtD
Bortezomib—Pancreatitis—Methotrexate—lymphatic system cancer	0.000209	0.000328	CcSEcCtD
Bortezomib—Pain—Mitoxantrone—lymphatic system cancer	0.000208	0.000327	CcSEcCtD
Bortezomib—Constipation—Mitoxantrone—lymphatic system cancer	0.000208	0.000327	CcSEcCtD
Bortezomib—Body temperature increased—Carmustine—lymphatic system cancer	0.000207	0.000325	CcSEcCtD
Bortezomib—Abdominal pain—Carmustine—lymphatic system cancer	0.000207	0.000325	CcSEcCtD
Bortezomib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000205	0.000321	CcSEcCtD
Bortezomib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000205	0.000321	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—lymphatic system cancer	0.000203	0.000318	CcSEcCtD
Bortezomib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000201	0.000315	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—lymphatic system cancer	0.0002	0.000313	CcSEcCtD
Bortezomib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000199	0.000312	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000198	0.000311	CcSEcCtD
Bortezomib—Abdominal pain—Vincristine—lymphatic system cancer	0.000198	0.00031	CcSEcCtD
Bortezomib—Body temperature increased—Vincristine—lymphatic system cancer	0.000198	0.00031	CcSEcCtD
Bortezomib—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000197	0.000308	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000195	0.000305	CcSEcCtD
Bortezomib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000194	0.000303	CcSEcCtD
Bortezomib—Hypersensitivity—Carmustine—lymphatic system cancer	0.000193	0.000303	CcSEcCtD
Bortezomib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000193	0.000302	CcSEcCtD
Bortezomib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000193	0.000302	CcSEcCtD
Bortezomib—Pneumonia—Methotrexate—lymphatic system cancer	0.000192	0.0003	CcSEcCtD
Bortezomib—Vomiting—Bleomycin—lymphatic system cancer	0.000191	0.000299	CcSEcCtD
Bortezomib—Infestation—Methotrexate—lymphatic system cancer	0.00019	0.000298	CcSEcCtD
Bortezomib—Infestation NOS—Methotrexate—lymphatic system cancer	0.00019	0.000298	CcSEcCtD
Bortezomib—Rash—Bleomycin—lymphatic system cancer	0.000189	0.000297	CcSEcCtD
Bortezomib—Dermatitis—Bleomycin—lymphatic system cancer	0.000189	0.000296	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000189	0.000296	CcSEcCtD
Bortezomib—Asthenia—Carmustine—lymphatic system cancer	0.000188	0.000295	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—lymphatic system cancer	0.000187	0.000293	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—lymphatic system cancer	0.000186	0.000291	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000185	0.00029	CcSEcCtD
Bortezomib—Hypersensitivity—Vincristine—lymphatic system cancer	0.000184	0.000289	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—lymphatic system cancer	0.000182	0.000284	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00018	0.000282	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—lymphatic system cancer	0.00018	0.000281	CcSEcCtD
Bortezomib—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00018	0.000281	CcSEcCtD
Bortezomib—Asthenia—Vincristine—lymphatic system cancer	0.00018	0.000281	CcSEcCtD
Bortezomib—Diarrhoea—Carmustine—lymphatic system cancer	0.000179	0.000281	CcSEcCtD
Bortezomib—Nausea—Bleomycin—lymphatic system cancer	0.000178	0.00028	CcSEcCtD
Bortezomib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000175	0.000274	CcSEcCtD
Bortezomib—Dizziness—Carmustine—lymphatic system cancer	0.000173	0.000272	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—lymphatic system cancer	0.000172	0.000269	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—lymphatic system cancer	0.000171	0.000268	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—lymphatic system cancer	0.000171	0.000268	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—lymphatic system cancer	0.000171	0.000268	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000169	0.000265	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000168	0.000263	CcSEcCtD
Bortezomib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000167	0.000261	CcSEcCtD
Bortezomib—Vomiting—Carmustine—lymphatic system cancer	0.000167	0.000261	CcSEcCtD
Bortezomib—Dizziness—Vincristine—lymphatic system cancer	0.000166	0.000259	CcSEcCtD
Bortezomib—Rash—Carmustine—lymphatic system cancer	0.000165	0.000259	CcSEcCtD
Bortezomib—Dermatitis—Carmustine—lymphatic system cancer	0.000165	0.000259	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—lymphatic system cancer	0.000165	0.000258	CcSEcCtD
Bortezomib—Headache—Carmustine—lymphatic system cancer	0.000164	0.000257	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000162	0.000253	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—lymphatic system cancer	0.00016	0.00025	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—lymphatic system cancer	0.000159	0.00025	CcSEcCtD
Bortezomib—Vomiting—Vincristine—lymphatic system cancer	0.000159	0.000249	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000159	0.000249	CcSEcCtD
Bortezomib—Rash—Vincristine—lymphatic system cancer	0.000158	0.000247	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—lymphatic system cancer	0.000158	0.000247	CcSEcCtD
Bortezomib—Headache—Vincristine—lymphatic system cancer	0.000157	0.000246	CcSEcCtD
Bortezomib—Nausea—Carmustine—lymphatic system cancer	0.000156	0.000244	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—lymphatic system cancer	0.000155	0.000243	CcSEcCtD
Bortezomib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000155	0.000243	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000154	0.000242	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000154	0.000241	CcSEcCtD
Bortezomib—Rash—Mitoxantrone—lymphatic system cancer	0.000154	0.000241	CcSEcCtD
Bortezomib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000154	0.000241	CcSEcCtD
Bortezomib—Chills—Methotrexate—lymphatic system cancer	0.000153	0.00024	CcSEcCtD
Bortezomib—Headache—Mitoxantrone—lymphatic system cancer	0.000153	0.000239	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—lymphatic system cancer	0.00015	0.000235	CcSEcCtD
Bortezomib—Erythema—Methotrexate—lymphatic system cancer	0.000149	0.000233	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—lymphatic system cancer	0.000149	0.000233	CcSEcCtD
Bortezomib—Nausea—Vincristine—lymphatic system cancer	0.000149	0.000233	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000146	0.000228	CcSEcCtD
Bortezomib—Nausea—Mitoxantrone—lymphatic system cancer	0.000145	0.000227	CcSEcCtD
Bortezomib—Back pain—Methotrexate—lymphatic system cancer	0.000144	0.000226	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—lymphatic system cancer	0.00014	0.00022	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000138	0.000216	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—lymphatic system cancer	0.000138	0.000216	CcSEcCtD
Bortezomib—Malaise—Methotrexate—lymphatic system cancer	0.000134	0.00021	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—lymphatic system cancer	0.000134	0.000209	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—lymphatic system cancer	0.000133	0.000209	CcSEcCtD
Bortezomib—Cough—Methotrexate—lymphatic system cancer	0.00013	0.000203	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—lymphatic system cancer	0.000129	0.000202	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—lymphatic system cancer	0.000127	0.000199	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—lymphatic system cancer	0.000127	0.000199	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—lymphatic system cancer	0.000127	0.000199	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000126	0.000197	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—lymphatic system cancer	0.000125	0.000196	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—lymphatic system cancer	0.000122	0.000192	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000121	0.00019	CcSEcCtD
Bortezomib—Infection—Methotrexate—lymphatic system cancer	0.000121	0.000189	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000119	0.000187	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000119	0.000186	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—lymphatic system cancer	0.000118	0.000185	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000117	0.000184	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—lymphatic system cancer	0.000116	0.000181	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—lymphatic system cancer	0.000113	0.000178	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000111	0.000173	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—lymphatic system cancer	0.00011	0.000172	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—lymphatic system cancer	0.000109	0.000171	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000108	0.00017	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000107	0.000168	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000106	0.000165	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000105	0.000164	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—lymphatic system cancer	0.000105	0.000164	CcSEcCtD
Bortezomib—Pain—Methotrexate—lymphatic system cancer	0.000104	0.000163	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—lymphatic system cancer	0.0001	0.000157	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	9.93e-05	0.000156	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—lymphatic system cancer	9.65e-05	0.000151	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—lymphatic system cancer	9.6e-05	0.00015	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—lymphatic system cancer	9.6e-05	0.00015	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—lymphatic system cancer	8.95e-05	0.00014	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—lymphatic system cancer	8.71e-05	0.000137	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—lymphatic system cancer	8.59e-05	0.000135	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—lymphatic system cancer	8.31e-05	0.00013	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—lymphatic system cancer	8.03e-05	0.000126	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—lymphatic system cancer	7.72e-05	0.000121	CcSEcCtD
Bortezomib—Rash—Methotrexate—lymphatic system cancer	7.66e-05	0.00012	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—lymphatic system cancer	7.65e-05	0.00012	CcSEcCtD
Bortezomib—Headache—Methotrexate—lymphatic system cancer	7.61e-05	0.000119	CcSEcCtD
Bortezomib—Nausea—Methotrexate—lymphatic system cancer	7.21e-05	0.000113	CcSEcCtD
